首页> 美国卫生研究院文献>Molecular Cancer >Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells
【2h】

Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells

机译:透明质酸-CD44相互作用促进乳腺癌细胞中c-Jun信号转导和miRNA21表达,导致Bcl-2表达和化学抗性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

MicroRNA-21 (miR-21) is associated with the development of solid tumors progression including breast cancer. In this study we investigated matrix hyaluronan (HA)-CD44 (a primary HA receptor) interaction with c-Jun N-Terminal Kinase (JNK)/c-Jun signaling in MDA-MB-468 breast cancer cells [a triple-negative (estrogen receptor-negative/progesterone receptor-negative/HER2-negative) breast cancer cell line]. Our results indicated that HA binding to CD44 promotes c-Jun nuclear translocation and transcriptional activation. Further analyses revealed that miR-21 is regulated by an upstream promoter containing AP1 binding site(s), and chromatin immunoprecipitation (CHIP) assays demonstrated that stimulation of miR-21 expression by HA/CD44 interaction is c-Jun-dependent in these breast cancer cells. This process results in an increase of the anti-apoptosis protein Bcl-2 and upregulation of inhibitors of the apoptosis family of proteins (IAPs) as well as chemoresistance in MDA-MB-468 cells. Treatment with c-Jun specific small interfering RNAs effectively blocks HA-mediated c-Jun signaling and abrogates miR-21 production as well as causes downregulation of survival proteins (Bcl-2 and IAPs) and enhancement of chemosensitivity. In addition, our results demonstrated that anti-miR-21 inhibitor not only downregulates Bcl-2/IAP expression but also increases chemosensitivity in HA-treated breast cancer cells. Together, these findings suggest that the HA/CD44-induced c-Jun signaling plays a pivotal role in miR-21 production leading to survival protein (Bcl-2/IAP) upregulation and chemoresistance in triple negative breast cancer cells such as MDA-MB-468 cell line. This novel HA/CD44-mediated c-Jun signaling pathway and miR-21 production provide a new drug target for the future intervention strategies to treat breast cancer.
机译:MicroRNA-21(miR-21)与包括乳腺癌在内的实体瘤进展有关。在这项研究中,我们研究了MDA-MB-468乳腺癌细胞中基质透明质酸(HA)-CD44(主要的HA受体)与c-Jun N末端激酶(JNK)/ c-Jun信号传导的相互作用[三阴性(雌激素受体阴性/孕激素受体阴性/ HER2阴性乳腺癌细胞株]。我们的结果表明HA与CD44结合可促进c-Jun核易位和转录激活。进一步的分析表明,miR-21受含有AP1结合位点的上游启动子调控,染色质免疫沉淀(CHIP)分析表明,HA / CD44相互作用刺激miR-21表达在这些乳腺癌中是c-Jun依赖性的癌细胞。该过程导致MDA-MB-468细胞中抗凋亡蛋白Bcl-2的增加和蛋白凋亡家族(IAPs)抑制剂的上调以及化学抗性。用c-Jun特异性小干扰RNA进行治疗可有效阻断HA介导的c-Jun信号传导并消除miR-21的产生,并引起存活蛋白(Bcl-2和IAP)的下调并增强化学敏感性。此外,我们的结果表明,抗miR-21抑制剂不仅下调Bcl-2 / IAP表达,而且还提高了HA治疗的乳腺癌细胞的化学敏感性。在一起,这些发现表明,HA / CD44诱导的c-Jun信号在miR-21产生中起关键作用,从而导致MDA-MB等三阴性乳腺癌细胞中的生存蛋白(Bcl-2 / IAP)上调和化学抗性。 -468细胞系。这种新颖的HA / CD44介导的c-Jun信号通路和miR-21的产生为治疗乳腺癌的未来干预策略提供了新的药物靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号